Why AstraZeneca Plc Is A Buy For Me

Pharma giant AstraZeneca plc (LON:AZN) is a turnaround opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical company AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been in the doldrums for a while now. The company’s share price has been becalmed by a succession of patent expiries and lack of successes in its drugs pipeline.

Last year the patent on Seroquel expired, and next year the patent on heartburn drug Nexium expires. The loss of exclusivity of these blockbusters has meant that sales and profits have been falling.

More innovative and less risk-averse

The lack of a clear strategy to reverse this decline cost chief executive Dave Brennan his job. But new chief executive Pascal Soriot has shown an impressive ability to sort out AstraZeneca’s troubles and reshape it as a company with a focus on areas that promise growth in the future.

He is encouraging the company to be more innovative, basing the company’s research activities in the buzzing ‘life sciences’ hub of Cambridge, which Soriot thinks could rival San Francisco and Boston. His aim is that the business feeds off this entrepreneurial spirit and is less risk-averse and more ambitious.

He is making considered acquisitions, often of biotech companies with bright ideas but small pockets, and he is focusing research in the areas of cardiovascular medicine, oncology and respiratory drugs.

A more future-proof company

He is a former executive of Roche, which, of all drugs companies, has been quickest off the mark in embracing the new boom in biologics and biotechnology. If Astra can future-proof itself in a similar way, then this company may just be a great turnaround opportunity.

The simple numbers show why AstraZeneca is a buy: the company is on a forward P/E ratio of just 9 (compared to 14 for GlaxoSmithKline), with a dividend yield of 6%. With profitability now stabilising after all the patent expiries, and with routes to growth such as emerging markets and biotech, this is a value/turnaround play with the potential for long-term growth.

For all these reasons, AstraZeneca is a buy.

One of the value plays of the year?

Personally, as an investor, value investing forms the central tenet of my investing philosophy. AstraZeneca’s low P/E ratio and high dividend yield make it one of the value and income plays of the moment.

If you already own AstraZeneca shares and are looking for more investing ideas, then I’d recommend you read our report “The Motley Fool’s Top Income Share For 2013”. It has been put together by our resident investing experts and is available without obligation and completely free.

> Prabhat owns shares in GlaxoSmithKline, but owns none of the other shares in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

This FTSE 100 stock has crashed nearly 70%! Would I be silly not to buy?

The share price of FTSE 100 icon Burberry is on the floor. But is now the time for this Fool…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

15% growth forecast in 12 months! This FTSE 100 firm is transforming accounting

Our author says the future of accounting is in automation. He thinks this FTSE 100 stock could continue to lead…

Read more »

Investing Articles

As easyJet predicts a record summer, is the share price primed for take-off?

The easyJet share price has had a disappointing year so far in 2024. But soaring summer bookings might just change…

Read more »

Growth Shares

Up 229%, this new kid on the block has caught my eye as a growth stock

Jon Smith eyes up a UK growth stock that was recently admitted to the FTSE 250 and that has shot…

Read more »

Investing Articles

What’s going on with the Fresnillo share price?

Following the release of it's latest production report, the Fresnillo share price is on the move, but what's next for…

Read more »

Dividend Shares

Is this top banking stock my ticket to a chunky passive income?

Our writer wants to build a passive income for the future. He wonders whether this UK bank stock could help…

Read more »

Investing Articles

Here’s why Aston Martin’s one of the best-performing UK stocks today!

Several UK stocks pushed upwards on 24 July, and this iconic, British car manufacturer was among the best performers. Why…

Read more »

Investing Articles

Down 85%, but I’m backing this FTSE 250 stock to fly like the Rolls-Royce share price

The Rolls-Royce share price has flown to the stars and Harvey Jones thinks it's too late to buy. So he's…

Read more »